Valion Bio (VBIO) Operating Expenses (2021 - 2025)
Valion Bio (VBIO) posted quarterly Operating Expenses of $2.3 million for Q3 2025, up 58.51% year-over-year from $1.5 million in Q3 2024, and up 17.61% quarter-over-quarter from $2.0 million in Q2 2025.
Valion Bio (VBIO) Operating Expenses (2021 - 2025) Analysis & Trends
Valion Bio's Operating Expenses history runs 5 years deep, the most recent figure standing at $2.3 million for Q3 2025.
- In Q3 2025, Operating Expenses rose 58.51% year-over-year to $2.3 million; the TTM figure through Dec 2025 stood at $5.9 million (up 3.87% YoY), while the FY2024 annual figure was $5.7 million, down 33.63% from the prior year.
- Operating Expenses for Q3 2025 stood at $2.3 million, up from $2.0 million in the prior quarter.
- The five-year high for Operating Expenses was $3.1 million in Q2 2022, with the low at $1.0 million in Q2 2021.
- The 5-year median for Operating Expenses is $2.0 million (2025), against an average of $1.9 million.
- The sharpest annual moves came in 2022 and 2024: Operating Expenses jumped 207.53% in 2022, then plunged 44.69% in 2024.
- Valion Bio's Operating Expenses stood at $2.3 million in 2021, then gained by 0.39% to $2.3 million in 2022, then declined by 2.17% to $2.2 million in 2023, then slumped by 44.69% to $1.2 million in 2024, then jumped by 87.94% to $2.3 million in 2025.
- Business Quant data shows VBIO's Operating Expenses at $2.3 million in Q3 2025, $2.0 million in Q2 2025, and $1.6 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.06 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 427.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 541.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -784.57 Mn |
| 10 | Valion Bio | 420,133.64 | -1.78 Mn | -45,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 2.34 Mn |
| Jun 30, 2025 | 1.99 Mn |
| Mar 31, 2025 | 1.56 Mn |
| Dec 31, 2024 | 1.24 Mn |
| Sep 30, 2024 | 1.48 Mn |
| Jun 30, 2024 | 1.30 Mn |
| Mar 31, 2024 | 1.65 Mn |
| Dec 31, 2023 | 2.25 Mn |
| Sep 30, 2023 | 1.87 Mn |
| Jun 30, 2023 | 2.19 Mn |
| Mar 31, 2023 | 2.23 Mn |
| Dec 31, 2022 | 2.30 Mn |
| Sep 30, 2022 | 2.65 Mn |
| Jun 30, 2022 | 3.14 Mn |
| Mar 31, 2022 | 2.31 Mn |
| Dec 31, 2021 | 2.29 Mn |
| Sep 30, 2021 | 1.20 Mn |
| Jun 30, 2021 | 1.02 Mn |
| Mar 31, 2021 | 1.08 Mn |